CN1091636A - 药物 - Google Patents

药物 Download PDF

Info

Publication number
CN1091636A
CN1091636A CN93112828A CN93112828A CN1091636A CN 1091636 A CN1091636 A CN 1091636A CN 93112828 A CN93112828 A CN 93112828A CN 93112828 A CN93112828 A CN 93112828A CN 1091636 A CN1091636 A CN 1091636A
Authority
CN
China
Prior art keywords
formula
chemical compound
group
piperidines
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93112828A
Other languages
English (en)
Chinese (zh)
Inventor
T·H·布朗
D·G·库帕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1091636A publication Critical patent/CN1091636A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN93112828A 1992-12-15 1993-12-14 药物 Pending CN1091636A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929226111A GB9226111D0 (en) 1992-12-15 1992-12-15 Madicaments
GB9226111.4 1992-12-15

Publications (1)

Publication Number Publication Date
CN1091636A true CN1091636A (zh) 1994-09-07

Family

ID=10726633

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93112828A Pending CN1091636A (zh) 1992-12-15 1993-12-14 药物

Country Status (8)

Country Link
EP (1) EP0674514A1 (fr)
JP (1) JPH08504419A (fr)
CN (1) CN1091636A (fr)
AU (1) AU5698394A (fr)
GB (1) GB9226111D0 (fr)
MX (1) MX9307946A (fr)
WO (1) WO1994013291A1 (fr)
ZA (1) ZA939317B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314973D0 (en) * 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
GB9411052D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Medicaments
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
AU2982595A (en) * 1994-07-14 1996-02-16 Smithkline Beecham Plc Benzocycloalkylamine derivatives as calcium chanel antagonists
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
EP0790235A1 (fr) * 1996-02-15 1997-08-20 Sankyo Company Limited Dérivés de diaryle-alkanes contenant un groupe alicyclique, leur préparation et leurs applications thérapeutiques et prophylactiques
CA2232147A1 (fr) * 1997-04-03 1998-10-03 F. Hoffmann-La Roche Ag Derives de la phenoxymethylpiperidine
US6110937A (en) * 1997-04-03 2000-08-29 Syntex Usa, Inc. Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain
AU1600599A (en) 1998-02-27 1999-09-15 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) * 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
CA2394633A1 (fr) * 1999-12-21 2001-06-28 Mitsubishi Pharma Corporation Agent therapeutique ou prophylactique pour trouble du systeme nerveux
EP1318988A2 (fr) 2000-09-11 2003-06-18 Sepracor, Inc. Ligands pour les recepteurs de monoamine et transporteurs, et procedes d'utilisation de ces derniers (neurotransmission)
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
WO2004078715A1 (fr) 2003-03-07 2004-09-16 Astellas Pharma Inc. Derive heterocyclique azote contenant du styryl 2,6-disubstitue
WO2005092885A1 (fr) 2004-02-27 2005-10-06 Eli Lilly And Company Derives de 4-amino-piperidine utilises en tant qu'inhibiteurs de l'absorption des monoamines
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7402684B2 (en) * 2005-09-21 2008-07-22 Decode Genectics Ehf. Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
CA2634701C (fr) * 2005-12-21 2014-07-29 Decode Genetics Ehf Inhibiteurs heterocycliques de lta4h a substitution biaryl, contenant de l'azote, destines au traitement d'inflammations
US10772858B2 (en) 2015-05-01 2020-09-15 Georgia State University Research Foundation, Inc. Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3381013A (en) * 1964-01-15 1968-04-30 Bristol Myers Co Heterocyclicamino ethers of benzylphenols
GB1096441A (en) * 1964-01-15 1967-12-29 Bristol Myers Co Ethers of benzyl phenols and a process for the preparation thereof
GB1203149A (en) * 1968-06-10 1970-08-26 Ici Ltd Piperidine derivatives
GB1319252A (en) * 1969-06-05 1973-06-06 Ciba Geigy Ag 1-phenyl-alkanols and process for making same
DE2728898A1 (de) * 1977-06-27 1979-01-18 Thomae Gmbh Dr K Neue morpholinderivate
DE2811952A1 (de) * 1978-03-18 1979-10-31 Merck Patent Gmbh Phenoxyalkylamine und verfahren zu ihrer herstellung
FR2443246A1 (fr) * 1978-12-05 1980-07-04 Pharmindustrie Nouveaux medicaments a base de derives de la phenyl-1 (piperidyl-4)-3 propanone-1
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
US4822778A (en) * 1988-01-19 1989-04-18 Gunnar Aberg Membrane stabilizing phenoxy-piperidine compounds and pharmaceutical compositions employing such compounds
US5169855A (en) * 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
MX9100513A (es) * 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
MX9100517A (es) * 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
GB9113031D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Compounds
JPH07503461A (ja) * 1992-01-28 1995-04-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー カルシウムチャンネル拮抗薬としての化合物

Also Published As

Publication number Publication date
ZA939317B (en) 1995-06-13
JPH08504419A (ja) 1996-05-14
AU5698394A (en) 1994-07-04
MX9307946A (es) 1994-08-31
GB9226111D0 (en) 1993-02-10
WO1994013291A1 (fr) 1994-06-23
EP0674514A1 (fr) 1995-10-04

Similar Documents

Publication Publication Date Title
CN1091636A (zh) 药物
CN1215045C (zh) 3,3－二苯基丙胺类化合物的新衍生物的稳定盐
CN1036920C (zh) 含杂环碳酸衍生物
CN1020095C (zh) 制备二氯苯胺衍生物的方法
CN1061963A (zh) 用作药物的4-取代的呱啶类
CN87100040A (zh) 二芳基烷基取代的烷基胺、其制备工艺方法、应用以及含有该类化合物的药物
CN1906180A (zh) 新的长效β－2－激动剂及其作为药物的用途
CN1050385A (zh) 制备具有类视黄酸生物活性的带有二取代的乙炔部分的化合物的方法以及中间体
CN1193961A (zh) 取代的苄氨基哌啶化合物
CN1251569A (zh) 新颖化合物,其用途及制法
CN1027368C (zh) 新型取代的喹啉衍生物的制备方法
CN1127254A (zh) 新的1,3-二氢-2H-吡咯并[2,3-b]吡啶-2-酮和噁唑并[4，5-b]吡啶-2(3H)-酮化合物，它们的制备方法以及含有它们的药物组合物
CN1032361C (zh) 咪唑并哒嗪化合物的制备方法
CN1062349A (zh) 用作药物的3-取代的呱啶类
CN1046330A (zh) 四氢苯并[c，d]吲哚5-羟色胺兴奋剂
CN1202155A (zh) 抗疟的喹啉衍生物
CN1131414A (zh) 可作为钙通道拮抗剂使用的氨基二氢化茚及有关化合物
CN1058207A (zh) 新的哌啶化合物及其制备方法
CN1050022A (zh) 去氢环黄皮酰胺衍生物的制备方法
CN1030584A (zh) 新型的噻吩衍生物及其制备方法
CN87107226A (zh) 内酰胺衍生物及其制备
CN1505624A (zh) 哌嗪子基衍生物及其作为pde4抑制剂的用途
CN1031754C (zh) 制备二噻烷衍生物的方法
CN1246312C (zh) 新的抗组胺哌啶衍生物及制备其的中间体
CN88102858A (zh) 可用作抗高血压剂的肼衍生物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication